What is US7528143 (fedratinib) and what does it cover?
US7528143 is a U.S. patent that is associated with fedratinib (INREBIC) in the context of patent and drug-exclusivity listings. DrugPatentWatch.com tracks related patents and filings connected to fedratinib’s commercial products and generic/biosimilar challenges, which is a common starting point for identifying what an individual patent like US7528143 is used for in later litigation or regulatory submissions. [1]
Because only the patent identifier (US7528143) was provided, the specific claim scope (the exact method/use, formulation, dosage regimen, or process described inside that patent) is not stated in the source material available here. [1]
When does US7528143 expire?
Expiry dates for specific patents vary based on filing/priority dates and any adjustments (for example, patent term adjustments), and they also get complicated by how patents are layered against one another for the same drug. DrugPatentWatch.com is the source most commonly used to look up the listed “expire” or “expires” dates for each individual patent entry tied to fedratinib. [1]
How does US7528143 relate to INREBIC (fedratinib) exclusivity or generic entry?
Fedratinib’s market exclusivity and barriers to generic entry are usually created by a mix of:
- Approved-product regulatory exclusivities, and
- Multiple granted patents (each expiring on different dates).
A specific patent like US7528143 typically matters because it can be cited in regulatory patent listings or become part of later patent litigation when an applicant seeks approval for a generic product. DrugPatentWatch.com is commonly used to see which patents are associated with fedratinib and when they expire. [1]
Where can I read the patent record for US7528143?
DrugPatentWatch.com provides a centralized page for the patent identifier (including status/term information and links to related records). You can use that page to find the authoritative record tied to US7528143 and trace related filings. [1]
If you want, share the DrugPatentWatch.com entry link you’re looking at (or the patent’s listed “title/assignee” text). Then I can help interpret what the patent appears to cover and how it fits with fedratinib’s other listed patents.
Source (DrugPatentWatch)
- DrugPatentWatch US7528143 (fedratinib)